Background
==========

Schizophrenia is a complex disease that develops in approximately 0.5-1.0% of the global population and inflicts physical suffering and mental anguish on the affected individuals and their families \[[@B1],[@B2]\]. The neurodevelopmental theory of schizophrenia postulates that abnormal neurodevelopment is one of the etiological factors of schizophrenia \[[@B3]-[@B6]\]. Recent studies suggest that schizophrenia may be a subtle disorder of brain development or plasticity \[[@B7]-[@B9]\].

Wnt proteins belong to a family of molecules that locally activate cell signaling pathways, regulating cell fate and playing an important role in development \[[@B10]\]. Evidence suggests that Wnt signaling and insulin signaling, which regulates glycogen synthase kinase-3 (GSK-3), may be important in schizophrenia \[[@B11]\]. Several lines of evidence support the association between signaling aberrations and schizophrenia. However, research has shown changes in gene expressions in schizophrenia \[[@B12]-[@B16]\], and, in particular, that some such changes affect GSK-3 \[[@B14],[@B17]-[@B19]\]. Researchers have also found Wnt signaling abnormalities associated with schizophrenia. For example, expressions of β-catenin proteins decreased in the brains of schizophrenia patients, presumably due to aberrant regulation of β-catenin degradation mediated by activated GSK-3β \[[@B20],[@B21]\]. Another report suggested the enhanced GSK-3β activity was secondary to diminished phosphorylation by Akt, since there is decreased Akt expression in schizophrenia patients\' brains \[[@B22]\]. Furthermore, researchers found increased Wnt-1 expression in the hippocampi of schizophrenia patients relative to normal subjects. Wnt-1 is an important molecule in the Wnt pathway \[[@B23]\]. Several studies have implicated Wnt signaling genes in bipolar disorder, as well as in schizophrenia. Researcher found that the frizzled-3 gene (FZD3), which encodes a receptor for Wnt ligands, was associated with schizophrenia in 3 different samples \[[@B24]-[@B26]\].

The wingless-type MMTV integration site family, member 2 (*WNT2*) gene is located at chromosome 7q31.2, a region that, in a genome scan study, showed evidence of a link to schizophrenia \[[@B27]\]. *WNT2*is one of the *WNT*genes that are expressed in a variety of tissues during development \[[@B28]\]. Knockout and expression studies in mice, zebra fish, and *Xenopus*have demonstrated *WNT*genes\' crucial roles in the development and patterning of the central nervous system \[[@B29]-[@B31]\]. WNT genes encode several signaling proteins that are essential in embryo patterning, cell proliferation, and cell determination \[[@B32],[@B33]\]. The WNT signaling pathway also includes several receptors expressed in both developing and mature nervous systems \[[@B34]\].

Previously, several studies have addressed whether the *WNT2*gene is associated with autism, a neurodevelopmental disorder \[[@B35]-[@B37]\]. Although Wassink et al. reported that one of *WNT2*SNPs (rs2024233 on exon 5) is associated with autism \[[@B35]\], following association studies did not find any significant associations with autism \[[@B36],[@B37]\]. In addition, Proitsi et al. performed a combined positional and candidate association screen, by identifying known *WNT*signaling genes, and showed that Dickkopf-4 was associated with schizophrenia \[[@B38]\]. There have been no published investigations of the association between *WNT2*genetic polymorphisms and schizophrenia, despite its potentially important developmental roles and its importance in genetics. In this study, therefore, we investigated the association between WNT2 polymorphisms and schizophrenia in a Korean population.

Methods
=======

Subjects
--------

For this study, we evaluated 288 schizophrenic patients (193 males, aged 42.98 ± 10.63 years \[mean ± SD\]; 95 females, aged 43.03 ± 10.65) and 305 controls with no clinical evidence of any disorders (147 males, 39.92 ± 5.82; 158 females, 36.55 ± 6.77). The schizophrenic patients met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) \[[@B39]\] criteria for schizophrenia. We reviewed each patient\'s medical record and rated the schizophrenic patients using the Brief Psychiatric Rating Scale (BPRS) \[[@B40]\], the Scale for the Assessment of Negative Symptoms (SANS) \[[@B41]\], and the operational criteria (OPCRIT) checklist \[[@B42]\].

To evaluate patients for schizophrenia with poor concentration, we used the OPCRIT Checklist. Of the many OPCRIT items, we selected only a few items, already described in our previous study, for use \[[@B43]\]. We determined which patients to place in the poor concentration subgroup according to patients\' subjective complaints of being unable to think clearly or make decisions (scoring: 1 for a duration of one week, 2 for two weeks, and 3 for one month) \[[@B42]\]. Thus, we examined 167 schizophrenic patients having poor concentration (116 males, 42.8 ± 10.0; 51 females, 41.9 ± 10.8) and 121 schizophrenic patients who had no such complaints (77 males, 43.6 ± 11.2; 44 females, 44.8 ± 10.7). We also analyzed the associations between the schizophrenic patients\' SNPs and their SANS scores (Table [1](#T1){ref-type="table"}). The genotype frequencies of rs6948009 was evaluated (A/A, n = 211; A/G, n = 71; G/G, n = 3) for the analysis with SANS scores.

###### 

*WNT2*SNPs genotype and allele frequencies in schizophrenia patients and healthy controls

                        Schizophrenia   Control                                                 
  --------------- ----- --------------- --------- ----- ------ ------------- ------------------ -----------
  rs39315         A/A   90              0.31      79    0.26   co-dominant   1.21 (0.95-1.54)   0.12
  5\'-near gene   A/G   137             0.48      150   0.49   dominant      1.38 (0.94-2.02)   0.1
                  G/G   61              0.21      76    0.25   recessive     1.20 (0.80-1.81)   0.38
                                                                                                
  rs17132543      A/A   97              0.34      98    0.32   co-dominant   1.14 (0.89-1.45)   0.3
  Intron4         A/G   138             0.48      145   0.48   dominant      1.16 (0.80-1.68)   0.43
                  G/G   53              0.18      62    0.2    recessive     1.22 (0.79-1.89)   0.37
                                                                                                
  rs3779548       A/A   127             0.44      135   0.44   co-dominant   0.97 (0.74-1.25)   0.8
  Intron4         A/G   128             0.44      136   0.45   dominant      0.99 (0.70-1.40)   0.96
                  G/G   33              0.11      34    0.11   recessive     0.88 (0.50-1.53)   0.65
                                                                                                
  rs733154        A/A   171             0.59      177   0.58   co-dominant   1.00 (0.74-1.33)   0.97
  Intron4         A/G   103             0.36      109   0.36   dominant      1.02 (0.72-1.44)   0.93
                  G/G   14              0.05      19    0.06   recessive     0.89 (0.42-1.92)   0.78
                                                                                                
  rs2024233       A/A   87              0.3       84    0.28   co-dominant   1.11 (0.87-1.43)   0.41
  3\'-UTR         A/G   148             0.51      157   0.51   dominant      1.15 (0.79-1.69)   0.46
                  G/G   53              0.18      64    0.21   recessive     1.14 (0.74-1.77)   0.54
                                                                                                
  rs4730775       G/G   176             0.61      184   0.6    co-dominant   0.89 (0.66-1.20)   0.45
  3\'-near gene   G/A   94              0.33      112   0.37   dominant      1.02 (0.71-1.45)   0.93
                  A/A   17              0.06      9     0.03   recessive     0.35 (0.14-0.85)   **0.017**

Freq, frequency; OR, odds ratio; CI, confidence interval.

We recruited control subjects who had been found mentally fit by a general health checkup program. All studies were carried out according to the guidelines of the Declaration of Helsinki \[[@B44]\]. We obtained written informed consent from each subject. The study was approved by the ethics review committee of the Medical Research Institute, Kyung Hee University Medical Center, Seoul, Republic of Korea.

SNP Genotyping
--------------

We selected 8 SNPs from *WNT2*genes in chromosome 7q31.2 by downloading all the SNPs typed in the *WNT2*genes from the HapMap database (<http://www.hapmap.org/>;genome build 35) and dbSNP database version 129. From these, we selected tag SNPs using the Tagger program\'s aggressive tagging option (Paul de Bakker, <http://www.broad.mit.edu/mpg/tagger/>), so as to capture SNPs with a minor allele frequency of \< 5% (*r*^2^\> 0.8). This gave 2 exonic SNPs (rs2024233 and rs1051751), 3 intronic SNPs (rs733154, rs3779548, and rs17132543), and 3 regulatory SNPs (thought to be the promoter; the intervals are 2000 bp up- and downstream between the genes) (rs6948009 \[869 bp downstream from the last nucleotide of the 3\'-UTR\], rs4730775 \[164 bp downstream from the last nucleotide of the 3\'-UTR\], and rs39315 \[219 bp upstream from the first nucleotide of the 5\'-UTR\]). In addition, we chose these SNPs because they were previously evaluated for relation to schizophrenia risk or showed evidence of functional significance. Figure [1](#F1){ref-type="fig"} shows the locations of the selected SNPs.

![**Gene map and single nucleotide polymorphisms (SNPs) in the *WNT2*gene on chromosome 7q31.2**. Exons are marked with boxes. The coding regions are black boxes. The first nucleotide is denoted as +1. The arrow indicates the location of each SNP.](1471-2350-11-78-1){#F1}

Using a commercially available Qiagen DNA Extraction kit (Qiagen, Tokyo, Japan), we extracted genomic DNA from blood samples that had been placed in EDTA. We amplified the genomic DNA using the primers shown in Table [2](#T2){ref-type="table"} for each SNP, sequenced the PCR products using an ABI Prism 377 automatic sequencer (PE Applied Biosystems, Foster City, California, USA), and analyzed the sequence data using SeqManII software (DNASTAR Inc., Madison, Wisconsin, USA).

###### 

Primer Sequences

  SNP          Sequence(5\'-3\')                 Product Size   Temperature
  ------------ --------------------------------- -------------- -------------
  rs39315      Forward CCTCCCTATGGGCTCTGTATT     450            60
               Reverse CACGGGTGCATGAAATGATGG                    
                                                                
  rs17132543   Forward AGCCTCTAGAGAAGTCCTGAAG    373            60
               Reverse CTCCCAACCACACTCACACACA                   
                                                                
  rs3779548    Forward GTGTGGCCTACTTTGCAGAAG     355            60
               Reverse TTCTCCAGCACCTAGACTGTG                    
                                                                
  rs733154     Forward GGATCCTTGATCGAGCAGAGCCA   301            60
               Reverse GACTGCAGCAGGAGAGACAGTTA                  
                                                                
  rs1051751    Forward TGGGCCCACAGAACGAGTATAAC   327            65
               Reverse CCAGAGCTTCCAGGCAGTCCT                    
                                                                
  rs2024233    Forward GTAACAAGGTGGGGACGTGTGT    319            62
               Reverse GAGATTCCATGGGTCACATGCA                   
                                                                
  rs4730775    Forward TGGGGATACAAGATTGGTGAAC    360            65
               Reverse GATGGCAGAAGCCAACCACTA                    
                                                                
  rs6948009    Forward GGTCATTTAGACTGAGACTCG     461            60
               Reverse CACCAATCCCTTCGCCTCTCT                    

Statistical analysis
--------------------

Using SNPstats, we assessed the Hardy-Weinberg equilibrium (HWE) for both controls and schizophrenia patients \[[@B45]\]. For the linkage disequilibrium (LD) block, we used the Haploview version 3.32 \[[@B46]\]. We inferred the haplotypes and their frequencies using the EM algorithm \[[@B47]\]. We used the multiple logistic regression model to calculate odds ratios (OR), 95% confidence intervals, and corresponding *p*values (controlling age and gender as covariables), to analyze the association between schizophrenia and both SNPs and haplotypes. Furthermore, we analyzed the association between the schizophrenia subgroup and both SNPs and haplotypes, using SNPstats, the HapAnalyzer version 1.0 \[[@B48]\], and Helixtree (Golden Helix Inc., MT, USA). We assessed the associations between SNPs and SANS scores, using one-way ANOVA to analyze the relationship between SANS scores and genotype frequencies in the schizophrenia subgroup. We calculated the power, given the sample size, using a genetic power calculator <http://pngu.mgh.harvard.edu/~purcell/gpc>\[[@B49]\], and, to reduce error, we adjusted the effective sample size (calculated sample size × 100/95). When we calculated the sample powers, we found our case-control study was sufficiently powerful to determine a positive association. In this study, we found sample powers of 0.8046 (rs39315, effective sample size, number of cases for 80% power = 284), 0.8493 (rs17132543, n = 252), 0.9338 (rs3779548, n = 188), 0.9677 (rs733154, n = 155), 0.9145 (rs2024233, n = 208), and 0.9689 (rs4730775, n = 154) for detecting a two-fold increased risk, assuming an *α*-level of 0.05. However, the sample powers in the divided schizophrenia subgroup (with or without poor concentration) were not sufficient (data not shown). We applied the Bonferroni correction by multiplying *P*values by the number of SNPs analyzed (*n*= 6).

Results
=======

Of the eight SNPs we examined, all were polymorphic. The genotype distributions of six SNPs (rs39315, rs17132543, rs3779548, rs733154, rs2024233, and rs4730775) were in HWE (*P*\> 0.05). We did not estimate one SNP (rs6948009) for the association analysis because its genotype distribution was not in HWE (*p*\< 0.05). Also, we excluded one SNP (rs1052751) from the analysis, since it was not polymorphic. Of these SNPs, one SNP (rs4730775) was weakly associated with schizophrenia. Despite this association (p = 0.017 in the recessive model), we could not prove the statistical significance of analysis after the Bonferroni correction. Thus, these results do not support a significant role for the *WNT2*sequence variation in the etiology of schizophrenia.

To further analyze the haplotype structure in our samples, we characterized the two LD blocks between the six *WNT2*SNPs (including the 5\'UTR and 3\'UTR) in the control subjects, using the pairwise D\'values (Figure [2](#F2){ref-type="fig"}). Per the criteria used by Gabriel et al. \[[@B50]\], the LD data revealed two haplotype blocks across *WNT2*. The D\' values from rs4730775 to rs32024233 and from rs37795488 to rs17132543 ranged between 0.95 and 0.99, indicating strong LD between each pair of markers (Figure [2](#F2){ref-type="fig"}). We performed a haplotype-based association analysis between the schizophrenic and control groups for different combinations of SNPs within *WNT2*, revealing two LD blocks (block 1, rs4730775 and rs32024233; block 2, rs37795488 and rs17132543). However, we did not detect significant associations between the haplotypes in block 1 or 2 and schizophrenia (all p-values of the analysis \> 0.05; Table [3](#T3){ref-type="table"}). We then assessed the gene and haplotype associations with these SNPs in the poor-concentration schizophrenia subgroup (determined using the OPCRIT Checklist). In this subgroup, the genotype distributions of the seven SNPs considered were in HWE (*p*\> 0.05). We then analyzed the genetic associations of these SNPs within the subgroup. The SNPs of the *WNT2*gene were not associated with poor concentration, a clinical symptom of schizophrenia (Table [4](#T4){ref-type="table"}). In addition, we assessed the associations between SNPs and SANS scores. No statistically significant differences appeared in the total SANS scores among the seven SNPs (Table [5](#T5){ref-type="table"}). To compare our genotypic results with different ethnic populations, we searched the human SNP database (<http://www.ncbi.nlm.nih.gov/SNP> dbSNP Build 130). This database presents genotype frequencies for the SNPs analyzed in this study (Table [6](#T6){ref-type="table"}). The control group\'s genotype distributions of the SNPs we analyzed are similar to those of Asian populations, especially the Japanese population (Table [6](#T6){ref-type="table"}).

![**Linkage disequilibrium (LD) blocks of the *WNT2*gene**. LD coefficient (\|D\'\|) and LD blocks among *WNT2*SNPs. Block 1 consists of rs4730775 and rs2024233. Block 2 comprises rs3779548 and rs17132543.](1471-2350-11-78-2){#F2}

###### 

*WNT2*SNPs haplotype frequencies in schizophrenia patients and healthy controls.

  Haplotype                  Schizophrenia               Control                                                                     
  --------------- ---------- ------------------- ------- ------------- ---------- ------- ---------- ------------- ----------------- -------------
                  HH         51                  0.19                  66         0.21               co-dominant   0.92(0.73-1.16)   0.4778
  HAP1 GG         H-         142                 0.52    0.44          163        0.51    0.46       dominant      0.91(0.64-1.31)   0.6236
                  \--        82                  0.3                   89         0.28               recessive     0.87(0.58-1.31)   0.5004
                                                                                                                                     
                  HH         31                  0.11                  37         0.12               co-dominant   1.04(0.82-1.32)   0.7506
  HAP2 GA         H-         121                 0.44    0.33          132        0.42    0.32       dominant      1.09(0.79-1.51)   0.604
                  \--        123                 0.45                  149        0.47               recessive     0.96(0.58-1.60)   0.8901
                                                                                                                                     
                  HH         15                  0.05                  11         0.03               co-dominant   1.07(0.81-1.42)   0.6325
  HAP3 AA         H-         93                  0.34    0.22          113        0.36    0.21       dominant      1.01(0.73-1.41)   0.9446
                  \--        167                 0.61                  194        0.61               recessive     1.61(0.73-3.57)   0.2405
                                                                                                                                     
                                                                                                                                     
                                                                                                                                     
  **Haplotype**              **Schizophrenia**           **Control**                                                                 
  **(Block 2)**   **Type**   **Freq**            **%**   **Freq**      **Freq**   **%**   **Freq**   **Models**    **OR(95% CI)**    **P value**
                                                                                                                                     
                  HH         50                  0.18                  65         0.2                co-dominant   0.90(0.72-1.14)   0.3894
  HAP1 AG         H-         130                 0.47    0.42          152        0.48    0.44       dominant      0.88(0.63-1.24)   0.4723
                  \--        95                  0.35                  101        0.32               recessive     0.86(0.57-1.30)   0.4881
                                                                                                                                     
                  HH         31                  0.11                  35         0.11               co-dominant   1.01(0.80-1.29)   0.912
  HAP2 GA         H-         123                 0.45    0.34          142        0.45    0.33       dominant      1.01(0.73-1.40)   0.9338
                  \--        121                 0.44                  141        0.44               recessive     1.03(0.62-1.72)   0.9181
                                                                                                                                     
                  HH         15                  0.05                  14         0.04               co-dominant   1.12(0.86-1.48)   0.4011
  HAP3 AA         H-         104                 0.38    0.24          114        0.36    0.22       dominant      1.13(0.82-1.57)   0.4568
                  \--        156                 0.57                  190        0.6                recessive     1.25(0.59-2.64)   0.5543

Freq, frequency; OR, odds ratio; CI, confidence intervals.

###### 

*WNT2*genotype frequencies in Korean schizophrenia patients with poor concentration

                        NPC   PC                                                   
  --------------- ----- ----- ------ ----- ------ ------------- ------------------ ------
  rs39315         A/A   40    33.1   50    29.9   co-dominant   0.97 (0.70-1.34)   0.85
  5\'-near gene   A/G   52    43.0   85    50.9   dominant      1.16 (0.70-1.92)   0.57
                  G/G   29    24.0   32    19.2   recessive     0.75 (0.43-1.33)   0.33
                                                                                   
  rs17132543      A/A   40    33.1   57    34.1   co-dominant   0.99 (0.71-1.38)   0.95
  Intron4         A/G   59    48.8   79    47.3   dominant      0.96 (0.59-1.58)   0.88
                  G/G   22    18.2   31    18.6   recessive     1.02 (0.56-1.87)   0.95
                                                                                   
  rs3779548       A/A   50    41.3   77    46.1   co-dominant   0.90 (0.63-1.27)   0.54
  Intron4         A/G   57    47.1   71    42.5   dominant      0.82 (0.51-1.32)   0.42
                  G/G   14    11.6   19    11.4   recessive     0.99 (0.47-2.06)   0.97
                                                                                   
  rs733154        A/A   67    55.4   104   62.3   co-dominant   0.84 (0.56-1.27)   0.41
  Intron4         A/G   50    41.3   53    31.7   dominant      0.71 (0.44-1.15)   0.17
                  G/G   4     3.3    10    6.0    recessive     1.77 (0.53-5.89)   0.34
                                                                                   
  rs2024233       A/A   38    31.4   49    29.3   co-dominant   1.11 (0.79-1.57)   0.53
  3\'-UTR         A/G   63    52.1   85    50.9   dominant      1.10 (0.66-1.83)   0.72
                  G/G   20    16.5   33    19.8   recessive     1.23 (0.67-2.28)   0.50
                                                                                   
  rs4730775       G/G   70    57.9   106   63.9   co-dominant   0.87 (0.59-1.28)   0.48
  3\'-UTR         G/A   45    37.2   49    29.5   dominant      0.76 (0.47-1.24)   0.27
                  A/A   6     5.0    11    6.6    recessive     1.29 (0.46-3.62)   0.62
                                                                                   
  rs6948009       G/G   87    73.1   124   74.7   co-dominant   0.80 (0.48-1.33)   0.39
  3\'-near gene   G/A   29    24.4   42    25.3   dominant      0.89 (0.52-1.53)   0.67
                  A/A   3     2.5    0     0      recessive     0.00 (0.00-NA)     0.02

Freq, frequency; NPC, nonpoor concentration; PC, poor concentration; OR, odds ratio; CI, confidence interval; N/A, not applicable.

###### 

Comparison of SANS scores between schizophrenic patient groups with different genotypes of *WNT2*.

                              SANS            
  --------------- ----- ----- ------- ------- -------
  rs39315         A/A   90    66.78   2.627   0.388
  5\'-near gene   A/G   137   63.76   2.239   0.866
                  G/G   61    64.41   2.831   0.55
                                              
  rs17132543      A/A   97    63.99   2.46    0.458
  Intron4         A/G   138   66.51   2.256   0.278
                  G/G   53    62.06   3.016   0.63
                                              
  rs3779548       A/A   127   66.42   2.139   0.689
  Intron4         A/G   128   65.17   2.257   0.124
                  G/G   33    57.48   4.394   0.062
                                              
  rs733154        A/A   171   66.11   1.946   0.371
  Intron4         A/G   103   63.32   2.375   0.684
                  G/G   14    60.5    6.791   0.429
                                              
  rs2024233       A/A   87    60.26   2.717   0.031
  3\'-UTR         A/G   148   67.59   2.034   0.461
                  G/G   53    64.68   3.319   0.311
                                              
  rs4730775       G/G   176   65.82   1.85    0.267
  3\'-UTR         G/A   94    64.23   2.63    0.619
                  A/A   17    58.82   6.56    0.427
                                              
  rs6948009       A/A   211   65.02   1.81    0.981
  3\'-near gene   A/G   71    64.94   2.5     0.307
                  G/G   3     52.33   3.38    0.406

SANS, Scale for the Assessment of Negative Symptoms; S.E., Standard Error; SNP, single nucleotide polymorphism.

###### 

*WNT2*SNPs genotype frequencies in each population

  SNP             Genotype   Schizophrenia   Control   Europe    China   Japan   Sub-Saharan African
  --------------- ---------- --------------- --------- --------- ------- ------- ---------------------
  rs39315         A/A        0.31            0.26      0.36      0.29    0.46    0.22
  5\'-near gene   A/G        0.48            0.49      0.41      0.62    0.43    0.44
                  G/G        0.21            0.25      0.22      0.09    0.11    0.34
                                                                                 
  P value                                              0.285     0.010   0.003   0.373
                                                                                 
  rs17132543      A/A        0.34            0.32      0.78      0.24    0.44    0.97
  Iintron4        A/G        0.48            0.48      0.22      0.58    0.47    0.03
                  G/G        0.18            0.20      0.00      0.18    0.09    0.00
                                                                                 
  P value                                              0.000     0.334   0.048   0.000
                                                                                 
  rs3779548       A/A        0.44            0.44      0.30      0.69    0.36    0.17
  Intron4         A/G        0.44            0.45      0.47      0.22    0.44    0.65
                  G/G        0.11            0.11      0.23      0.09    0.20    0.18
                                                                                 
  P value                                              0.031     0.001   0.180   0.000
                                                                                 
  rs733154        A/A        0.59            0.58                0.85    0.62    0.31
  Intron4         A/G        0.36            0.36      No data   0.13    0.31    0.37
                  G/G        0.05            0.06                0.03    0.08    0.33
                                                                                 
  P value                                              N/A       0.000   0.675   0.000
                                                                                 
  rs1051751       G/G        1.00            1.00      1.00      1.00    0.98    1.00
  Exon 5          G/T        0.00            0.00      0.00      0.00    0.02    0.00
  Cys294Phe       T/T        0.00            0.00      0.00      0.00    0.00    0.00
                                                                                 
  P value                                              N/A       N/A     N/A     N/A
                                                                                 
  rs2024233       A/A        0.30            0.28      0.50      0.29    0.34    0.54
  3\'-UTR         A/G        0.51            0.51      0.40      0.44    0.50    0.41
                  G/G        0.18            0.21      0.10      0.27    0.16    0.05
                                                                                 
  P value                                              0.003     0.526   0.531   0.000
                                                                                 
  rs4730775       G/G        0.61            0.60      0.37      0.71    0.62    0.46
  3\'-near gene   G/A        0.33            0.37      0.36      0.27    0.29    0.45
                  A/A        0.06            0.03      0.27      0.02    0.09    0.09
                                                                                 
  P value                                              0.000     0.261   0.135   0.060
                                                                                 
  rs6948009       A/A        0.74            0.53                0.95    0.93    
  3\'-near gene   A/G        0.25            0.45      No data   0.05    0.05    No data
                  G/G        0.01            0.02                0.00    0.02    
                                                                                 
  P value                                              N/A       0.000   0.000   N/A

From database <http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp>. We estimated all p-values via comparisons between the control group of our sample and each population. N/A, not applicable.

Discussion
==========

The *WNT2*gene and its chromosomal location have received attention as a candidate gene with regard to autism. Given the similarities between autistic disorders and schizophrenia (as a neurodevelopmental disorder), we investigated whether *WNT2*gene variations act as risk factors for schizophrenia in a Korean sample. The results suggest that *WNT2*may not be involved in the pathogenesis of schizophrenia. Of all the SNPs and haplotypes analyzed, only one SNP (rs4730775) showed a weak association with the disorder. However, the significance disappeared after the Bonferroni correction for multiple testing (p = 0.102, Table [1](#T1){ref-type="table"}). In addition, we investigated the LD between the *WNT2*SNPs and performed a haplotype analysis between the schizophrenia and control subjects. We could not find any association between *WNT2*and schizophrenia, indicating that there is no genetic association between *WNT2*and schizophrenia.

To further analyze the association test between clinical symptoms and SNP genotypes, we evaluated other symptoms, from the OPCRIT checklist and the total SANS scores. However, we found no statistically significant association between any symptom in OPCRIT (Table [4](#T4){ref-type="table"}) and total SANS score (Table [5](#T5){ref-type="table"}). We compared our genotype frequencies with the human SNP database <http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp>, to show ethnic similarities and differences. The genotype frequencies of our study sample resemble those of the Japanese and Chinese Hapmap populations (Table [6](#T6){ref-type="table"}). Further studies are necessary to elucidate (i) whether another case-control study is appropriate and (ii) whether promoter SNPs can affect the expression of *WNT2*. To confirm or refute the lack of association between the *WNT2*gene and schizophrenia, replication studies with adequate sample sizes, or studies with additional SNPs not analyzed in the present study, may be required.

This report has several limitations. First, the sample size may not have been sufficient to detect associations of smaller effects on schizophrenia. We estimated that this sample had more than 0.8 powers to detect association, with the gene exerting a genotypic relative risk of approximately 2. However, schizophrenia appears to be a very genetically complex disease, and the *WNT2*gene risks may be smaller than 2. Second, when we designed the experiment, the versions of the HapMap database and dbSNP database were slightly different compared to their present forms, and, as a result, our selection of SNPs provided incomplete coverage of currently-known common variations in the *WNT2*gene. Furthermore, the present databases showed different locations for some SNP from previous databases. Consequently, we may have missed some of the relevant associations of *WNT2*genes.

Conclusions
===========

We investigated possible associations between *WNT2*gene SNPs and schizophrenia, and the results were negative. For that reason, it appears the SNPs of *WNT2*may not influence the development of schizophrenia in the Korean population, but, still, additional genetic studies will help develop understanding of the precise mechanisms underlying pathogenesis in schizophrenic patients.
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